Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Advair "Approvable" At FDA; Flovent Tops $1 Bil. In 1999

Executive Summary

Glaxo Wellcome will respond to an FDA "approvable" letter for the asthma product Advair Diskus by Feb. 18, Chairman Richard Sykes indicated during a Feb. 16 analysts conference.

You may also be interested in...



Glaxo's Advair Combo Gets Broad Asthma Indication From FDA

Glaxo Wellcome's Advair Diskus will carry a broad indication for asthma patients requiring combination beta agonist/corticosteroid therapy.

Glaxo's Advair Combo Gets Broad Asthma Indication From FDA

Glaxo Wellcome's Advair Diskus will carry a broad indication for asthma patients requiring combination beta agonist/corticosteroid therapy.

Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely

Glaxo Wellcome intends to compete in the diabetes market with SmithKline Beecham's Avandia, Glaxo Chairman Richard Sykes indicated at an analysts earnings conference Feb. 16.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel